Use of Recombinant Human Follicle-Stimulating Hormone for In Vitro Fertilization-Embryo Transfer After Severe Systemic Immunoglobulin E-Mediated Reaction to Urofollitropin

Objective: To report the successful use of recombinant human FSH in a patient with a history of a severe systemic immunoglobulin E (IgE)-mediated reaction to urofollitropin.Setting: University hospital.Patient(s): A 38-year-old infertility patient who had experienced a whole-body rash with hives, tachycardia, fever, and other symptoms after urofollitropin administration, with confirmation of IgE-mediated sensitivity to urofollitropin by intradermal skin testing.Intervention(s): In vitro fertilization-ET after the use of recombinant human FSH to stimulate ovarian follicular development.Result(s): Establishment of a clinical pregnancy.Conclusion(s): Our case provides evidence for the involvement of nongonadotropin proteins as the direct cause of some adverse reactions from conventional urine-derived human FSH preparations.